Press coverage about G1 Therapeutics (NASDAQ:GTHX) has trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. G1 Therapeutics earned a news impact score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.8673419417536 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Shares of NASDAQ GTHX opened at $36.29 on Tuesday. The firm has a market capitalization of $1,184.58 and a PE ratio of -10.17. G1 Therapeutics has a 1 year low of $12.04 and a 1 year high of $42.78.

How to Become a New Pot Stock Millionaire

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings data on Wednesday, February 21st. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.02). research analysts anticipate that G1 Therapeutics will post -2.47 EPS for the current year.

GTHX has been the subject of a number of analyst reports. BidaskClub cut shares of G1 Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 3rd. Needham & Company LLC increased their price objective on shares of G1 Therapeutics to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, March 13th. JPMorgan Chase reissued an “overweight” rating and issued a $39.00 price objective (up from $33.00) on shares of G1 Therapeutics in a research note on Tuesday, March 6th. Zacks Investment Research raised shares of G1 Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 26th. Finally, BTIG Research initiated coverage on shares of G1 Therapeutics in a research note on Tuesday, December 19th. They issued a “buy” rating and a $38.00 price objective for the company. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. G1 Therapeutics presently has a consensus rating of “Buy” and an average target price of $38.20.

In related news, insider Rajesh Malik sold 3,776 shares of the firm’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $38.18, for a total transaction of $144,167.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Jennifer K. Moses sold 750 shares of the firm’s stock in a transaction on Thursday, April 5th. The shares were sold at an average price of $37.47, for a total transaction of $28,102.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 9,802 shares of company stock valued at $284,945.

TRADEMARK VIOLATION NOTICE: This story was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.dailypolitical.com/2018/04/17/g1-therapeutics-gthx-earns-news-impact-score-of-0-17.html.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

Insider Buying and Selling by Quarter for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.